TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05694117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training
Description: The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions). Participants in the RTG completed four sets of each movement, with two to three minutes of rest between each set.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taichi exercise and resistance training
Description: The training of the Taichi exercise and resistance training group consisted of two cycles, the first cycle was aimed at learning and consolidating Taichi exercise, and the second cycle was aimed at improving and consolidating. The Taichi exercise and resistance training group was scheduled for 30 min of Taichi exercise per training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Randomly selected exercise program
Description: Participants in the randomly selected exercise program group who chose Yijinjing exercise were required to complete one hour of Yijinjing exercise training, and those who chose Yijinjing exercise hybrid strength training had to complete half an hour of Yijinjing training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
Study: NCT03564873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine
Description: Phase I is a dose escalation phase. Patients will be enrolled into one of three cohorts to receive omacetaxine subcutaneously (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine
Description: Phase II is a maximum tolerated dose phase. Phase I will determine the maximum tolerated dose (highest amount that can be safely administered). Patients will receive omacetaxine subcutaneously at the maximum tolerated dose (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
Study: NCT04038645

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental group (laser)
Description: The patients will receive infrared LEDs in 6 points using a mask developed for the research . The irradiations will be performed with red LED ( wavelength = 660 nm) with output power of 100 milliwatt. During application of the LED both patient and operator will wear goggles.~The red diode laser will be used. The power of the device is 100 mW and the wavelength used was 660nm (± 10nm). The diameter of the fiber optic of the apparatus has 600 μm, therefore a spot (area) of 0.002826cm2. The energy delivered per point is 1 Joule. 10 seconds of application is required. As 6 points are irradiated, the total energy delivered is 6 Joules. The energy density is 354 J / cm2 and the power density would be 35.4 W / cm2. The points will be determined by the same operator, obeying the protocol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group (Placebo)
Description: Patients will receive the LED at the same points recommended for the experimental group, but will be off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of the application of the laser. The questionnaire to assess the impact of treatment on quality of life will be applied at baseline and after 8 days as well as the evaluation of serum CRP.
Study: NCT04385745

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biodegradable Intramedullary Nailing (BIN)
Description: Unstable forearm shaft fractures are treated by the study method (BIN) or the control method (ESIN).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biodegradable Intramedullary Nailing (BIN)
Description: Unstable forearm shaft fractures are treated by the study method (BIN) or the control method (ESIN).
Study: NCT03564873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
Study: NCT04129255

Intervention type: DRUG
Group type: OTHER
Intervention: Octreotide Acetate
Description: administration every 28 days
Study: NCT00972231

Intervention type: OTHER
Intervention: Medical Chart Summary
Description: Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.

Intervention type: OTHER
Intervention: Medical Chart Summary
Description: Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.
Study: NCT01274962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: * Oxaliplatin\* 85 mg/m2 IV in 500 mL of D5W over 120 minutes~* Folinic Acid (Leucovorin)\* 400 mg/m2 IV in 250 ml D5W over 120 minutes~* 5-Fluorouracil (5-FU) 400 mg/m2 IV bolus, after Folinic Acid~* 5-Fluorouracil\*\* 2400 mg/m2 IV over 46 h in D5W to a total volume of 92 mL by continuous infusion at 2 mL/hour.~* Repeat every 14 days for 6 cycles in the arm A and to be completed with 6 cycles after surgery and 12 cycles in arm B.~If necessary the schedule may be modified +/- 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: * Oxaliplatin\* 85 mg/m2 IV in 500 mL of D5W over 120 minutes~* Folinic Acid (Leucovorin)\* 400 mg/m2 IV in 250 ml D5W over 120 minutes~* 5-Fluorouracil (5-FU) 400 mg/m2 IV bolus, after Folinic Acid~* 5-Fluorouracil\*\* 2400 mg/m2 IV over 46 h in D5W to a total volume of 92 mL by continuous infusion at 2 mL/hour.~* Repeat every 14 days for 6 cycles in the arm A and to be completed with 6 cycles after surgery and 12 cycles in arm B.~If necessary the schedule may be modified +/- 3 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: high dose rate endorectal brachytherapy
Description: High dose rate endorectal brachytherapy, consisting in a total dose of 26 Gy in 4 daily fractions of 6.5 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: high dose rate endorectal brachytherapy
Description: High dose rate endorectal brachytherapy, consisting in a total dose of 26 Gy in 4 daily fractions of 6.5 Gy.
Study: NCT02119052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octeotride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04436718

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Daily pocus exam
Description: Daily evaluation of lung ultrasound for B line artifacts plus IVC assessments
Study: NCT03368391

Intervention type: DRUG
Group type: OTHER
Intervention: tetracaine HCl and oxymetazoline HCL
Description: 0.4 mL HCl and oxymetazoline HCl administered intranasally

Intervention type: DRUG
Group type: OTHER
Intervention: tetracaine HCl and oxymetazoline HCL
Description: 0.4 mL HCl and oxymetazoline HCl administered intranasally
Study: NCT03521167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intraoperatively use. start dexmedetomidine infusion at 0.5 mcg/kg/min after anesthesia induction, and continue up to 1 hour prior to extubation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: Postoperatively use. 300 mg PO TID starting POD1 until discharge Use lower dose for \>65y or if patient having significant sedation/dizziness

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Postoperatively use. 300 mg PO TID starting POD1 until discharge Use lower dose for \>65y or if patient having significant sedation/dizziness

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tylenol
Description: Postoperatively use. 1000 mg PO Q8hr starting POD0 until discharge (max 3000 mg in 24hrs) Reduce to 650 mg PO Q6h if \<70kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol
Description: Postoperatively use. 1000 mg PO Q8hr starting POD0 until discharge (max 3000 mg in 24hrs) Reduce to 650 mg PO Q6h if \<70kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin Pill
Description: Pre-operatively use. 300mg PO up to 1 hour before OR time Reduce to 100 mg PO in patients \>65y or with GFR \< 50 Consider dose reduction in patients with sleep apnea

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin Pill
Description: Pre-operatively use. 300mg PO up to 1 hour before OR time Reduce to 100 mg PO in patients \>65y or with GFR \< 50 Consider dose reduction in patients with sleep apnea

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tylenol Pill
Description: Pre-operatively use. 1000 mg PO up to 1 hour before OR time Reduce to 650 mg PO if \<70kg Don't use if h/o liver disease or anticipated liver injury (right heart failure, pulmonary hypertension, etc leading to systemic venous congestion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol Pill
Description: Pre-operatively use. 1000 mg PO up to 1 hour before OR time Reduce to 650 mg PO if \<70kg Don't use if h/o liver disease or anticipated liver injury (right heart failure, pulmonary hypertension, etc leading to systemic venous congestion)
Study: NCT03368391

Intervention type: DRUG
Group type: OTHER
Intervention: tetracaine HCl and oxymetazoline HCL
Description: 0.4 mL HCl and oxymetazoline HCl administered intranasally
Study: NCT03641469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green Sun Dynamic Brace
Description: Change from standard-of-care TLSO to GSM brace
Study: NCT01880268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI-controlled neurorehabilitation device
Description: Brain computer interface (BCI) -controlled neurorehabilitation device uses a participant's EEG to control with movements of an ordinary rehabilitation device (an upper limb ergometry, arm bike)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI-controlled neurorehabilitation device
Description: Brain computer interface (BCI) -controlled neurorehabilitation device uses a participant's EEG to control with movements of an ordinary rehabilitation device (an upper limb ergometry, arm bike)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation therapy
Description: Standard rehabilitation therapy for patient with stroke includes 1 hour of physical therapy and 1 hour of occupational therapy
Study: NCT03368391

Intervention type: DRUG
Group type: OTHER
Intervention: 2% Lidocaine with 1:100,000 epinephrine
Description: 2.5 mL of 2% Lidocaine with 1:100,000 epi will be infiltrated at anterior teeth

Intervention type: DRUG
Group type: OTHER
Intervention: 2% Lidocaine with 1:100,000 epinephrine
Description: 2.5 mL of 2% Lidocaine with 1:100,000 epi will be infiltrated at anterior teeth

Intervention type: DRUG
Group type: OTHER
Intervention: 2% Lidocaine with 1:100,000 epinephrine
Description: 2.5 mL of 2% Lidocaine with 1:100,000 epi will be infiltrated at anterior teeth

Intervention type: DRUG
Group type: OTHER
Intervention: 3% Mepivacaine with 1:100,000 epinephrine
Description: 2.5 mL of 3% Mepivacaine will be infiltrated at anterior teeth

Intervention type: DRUG
Group type: OTHER
Intervention: 3% Mepivacaine with 1:100,000 epinephrine
Description: 2.5 mL of 3% Mepivacaine will be infiltrated at anterior teeth

Intervention type: DRUG
Group type: OTHER
Intervention: 3% Mepivacaine with 1:100,000 epinephrine
Description: 2.5 mL of 3% Mepivacaine will be infiltrated at anterior teeth

Intervention type: DRUG
Group type: OTHER
Intervention: saline intranasal
Description: 0.4 mL intranasal saline will be administered as a placebo

Intervention type: DRUG
Group type: OTHER
Intervention: saline intranasal
Description: 0.4 mL intranasal saline will be administered as a placebo

Intervention type: DRUG
Group type: OTHER
Intervention: saline intranasal
Description: 0.4 mL intranasal saline will be administered as a placebo

Intervention type: DRUG
Group type: OTHER
Intervention: saline infiltration
Description: 2.8 mL of saline will be infiltrated at anterior teeth as a placebo

Intervention type: DRUG
Group type: OTHER
Intervention: saline infiltration
Description: 2.8 mL of saline will be infiltrated at anterior teeth as a placebo

Intervention type: DRUG
Group type: OTHER
Intervention: saline infiltration
Description: 2.8 mL of saline will be infiltrated at anterior teeth as a placebo
Study: NCT00622362

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DEPIGOID Dermatophagoides pteronyssinus
Description: Subcutaneous administration:0.5 ml/month during 1 year

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polymerized TOL of Dermatophagoides pteronyssinus
Description: Sublingual immunotherapy. Two drops daily during 1 year

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Sublingual immunotherapy. Two drops daily during 1 year
Study: NCT00752076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cancer cell lines establishment
Description: Detection of epithelial growth factor receptor (EGFR) mutation in malignant pleural effusion of lung cancer patients and cancer cell lines establishment
Study: NCT02414464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide
Description: Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP 35% gel was applied to the vestibular faces of these teeth.~In the present study, the Whiteness HP 35% gel was applied without an external auxiliary source. As this is not a self-catalyzed system, the gel was removed after each 15-minute application and reapplied two more times, totaling 45 minutes of contact with the teeth.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide
Description: Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 35% gel was applied to the vestibular faces of these teeth for 40 minutes in each session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% hydrogen peroxide
Description: Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 20% gel was applied to the vestibular faces of these teeth 50 minutes in each session.
Study: NCT02748174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Files
Description: Patients will be given a link to download audio files. They consist of breathing techniques, imaging, progressive relaxation, and more. Patients will be asked to perform 20 minutes of relaxation therapy at least 3 times per week. Patients will record their headache frequency and intensivy, in addition to other symptoms, and the frequency of practiving the behavioral therapy using Curelator Headache.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Files
Description: Patients will be given a link to download audio files. They consist of breathing techniques, imaging, progressive relaxation, and more. Patients will be asked to perform 20 minutes of relaxation therapy at least 3 times per week. Patients will record their headache frequency and intensivy, in addition to other symptoms, and the frequency of practiving the behavioral therapy using Curelator Headache.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Files
Description: Patients will be given a link to download audio files. They consist of breathing techniques, imaging, progressive relaxation, and more. Patients will be asked to perform 20 minutes of relaxation therapy at least 3 times per week. Patients will record their headache frequency and intensivy, in addition to other symptoms, and the frequency of practiving the behavioral therapy using Curelator Headache.
Study: NCT02189967

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional fractionation
Description: In this treatment arm patients will receive radiotherapy with the currently used conventional fractionation schedule i.e. 5 fractions per week, 2 Gy single dose.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: accelerated fraction
Description: In this treatment arm patients will receive radiotherapy with an accelerated fractionation schedule i.e. 7 fractions per week, 2 Gy single dose.
Study: NCT00619242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 2 tablets with water by mouth twice a day for two weeks.
Study: NCT03241550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazonium sulfate - intravenous
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazonium sulfate - intravenous
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazonium sulfate - intravenous
Description: IV infusion
Study: NCT04037254

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gonadotrophin Releasing Hormone
Description: Receive standard of care GnRH agonist androgen suppression therapy
Study: NCT03241550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazonium sulfate - oral
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazonium sulfate - oral
Description: Oral
Study: NCT04037254

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotrophin Releasing Hormone
Description: Receive standard of care GnRH agonist androgen suppression therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gonadotrophin Releasing Hormone
Description: Receive standard of care GnRH agonist androgen suppression therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo standard of care IMRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo standard of care IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo standard of care IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO
Study: NCT01809691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-700
Description: 300 mg, PO, twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: 50 mg, PO, q daily
Study: NCT02477943

Intervention type: DEVICE
Intervention: Advanced MRI Neuroimaging
Description: Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
Study: NCT02180711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT03067467

Intervention type: DRUG
Intervention: Hyperpolarized 13C-Pyruvate
Description: Hyperpolarized 13C-pyruvate IV bolus followed by brain MRSI.

Intervention type: DRUG
Intervention: Gadolinium
Description: Brain MRI performed with and without gadolinium-based contrast.
Study: NCT01142999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunflower oil
Description: One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
Study: NCT06642779

Intervention type: BEHAVIORAL
Intervention: VFQ- 25 (Visual Function Questionnaire)
Description: VFQ-25 questionnaire was used to evaluate patient satisfaction at the M3 and M12 visits.

Intervention type: BEHAVIORAL
Intervention: VFQ- 25 (Visual Function Questionnaire)
Description: VFQ-25 questionnaire was used to evaluate patient satisfaction at the M3 and M12 visits.
Study: NCT01142999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.